Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Tempe, Arizona Clinical Trials

A listing of Tempe, Arizona clinical trials actively recruiting patient volunteers.

RESULTS

Found (129) clinical trials

Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

To estimate the clinical benefit of REGN2810 monotherapy for patients with metastatic (nodal or distant) cutaneous squamous cell carcinoma (CSCC) (Groups 1 and 3) or with unresectable locally advanced CSCC (Group 2), as measured by overall response rate (ORR), according to central review.

Phase

7.89 miles

Learn More »

A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus

This will be a 12-week, randomized, double-blind, placebo-controlled, 4-arm, parallel group, multi-center study to evaluate the safety and efficacy of LGD-6972 in subjects with T2DM inadequately controlled on metformin monotherapy (a stable [≥12 weeks], daily dose of ≥1000mg at randomization). Subjects with T2DM will be treated with one of 3 ...

Phase

7.94 miles

Learn More »

Study of ISIS 703802 in Subjects With Hypertriglyceridemia Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease

This is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, including tolerability, of ISIS 703802 and to assess the efficacy of different doses and dosing regimens of ISIS 703802 on glucose and lipid metabolism, and liver fat in subjects with Hypertriglyceridemia, Type 2 Diabetes Mellitus (T2DM), and ...

Phase

7.94 miles

Learn More »

A POC and Dose-Ranging Study of HTD1801 in PSC Patients

This study evaluates HTD1801 in the treatment of Primary Sclerosing Cholangitis (PSC) in adults. The subjects will be randomised to 3 treatment groups, to receive 500mg, 1000mg and placebo, bid.

Phase

7.94 miles

Learn More »

Safety Tolerability and Efficacy of a Combination Treatment of Tropifexor (LJN452) and Cenicriviroc (CVC) in Adult Patients With Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis. (TANDEM)

The purpose of this study is to assess the safety, tolerability, and efficacy of a combination treatment of tropifexor (LJN452) and cenicriviroc (CVC) in adult patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis.

Phase

7.94 miles

Learn More »

A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab or With Spartalizumab and Carboplatin or With Carboplatin in Patients With Advanced Triple-negative Breast Cancer

The purpose of this study is to assess the efficacy, safety, and PK characteristics of the following three combinations: i) LAG525 + spartalizumab; ii) LAG525 + spartalizumab + carboplatin, and iii) LAG525 + carboplatin in subjects with advanced TNBC and up to one prior line of systemic treatment for metastatic ...

Phase

7.94 miles

Learn More »

A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)

Randomized, double-blind, placebo-controlled, parallel-group study comparing multiple doses of HTD1801 to placebo.

Phase

7.94 miles

Learn More »

The XENERA -1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Post-menopausal Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread

The main objective of the trial is to assess the anti-tumor activity of xentuzumab in combination with everolimus and exemestane over everolimus and exemestane in post menopausal patients with HR+/ HER2- advanced or metastatic breast cancer and non-visceral disease.

Phase

7.94 miles

Learn More »

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)

This study will evaluate the safety and efficacy of combination therapy of lenvatinib (E7080/MK-7902) and pembrolizumab following approximately 2 years of pembrolizumab therapy and approximately 2 years or more lenvatinib therapy in adult participants with unresectable or advanced melanoma who have been exposed to anti-PD-1/L1 agents approved for unresectable or ...

Phase

7.94 miles

Learn More »

Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel Syndrome

This study will evaluate the efficacy and safety of vibegron, a beta-3 adrenergic receptor (3-AR) agonist, in the treatment of pain associated with irritable bowel syndrome (IBS) due to IBS with predominant diarrhea (IBS-D) or mixed episodes of diarrhea and constipation (IBS-M).

Phase

7.94 miles

Learn More »